Brand: Orion Market Research
SKU: OMR2021673
Price: 2400 USD
Availability: InStock

Advanced Therapy Medicinal Products Market

SHARE ON:

Advanced Therapy Medicinal Products Market Size, Share & Trends Analysis Report, By Product Type (Gene Therapy, Cell Therapy, Tissue Engineered Products, Combined ATMPs), By Therapy Type (Autologous, Allogeneic), By Technology Platform (Viral Vector-Based, Non-Viral Delivery Systems, Gene Editing), By Application (Oncology, Rare Genetic Disorders, Cardiovascular, Neurological, Musculoskeletal, Ophthalmology, Immunological), By End User (Hospitals, Specialty Clinics, Research Institutes, Academic Medical Centers), Forecast Period (2026-2035)

Published: May 2026 | Report Code: OMR2021673 | Category : Pharmaceuticals | Delivery Format: /

Industry Overview

Advanced Therapy Medicinal Products (ATMP) market was valued at $28.5 billion in 2025 and is projected to reach $147.4 billion by 2035, growing at a CAGR of 17.9% during 2026–2035. A key growth driver is the increasing prevalence of chronic and rare diseases. According to the World Health Organization (WHO), non-communicable diseases account for nearly 74% of global deaths, significantly increasing the demand for advanced therapeutic solutions. Additionally, the U.S. Food and Drug Administration (FDA) has approved a growing number of gene and cell therapies, with projections indicating 10–20 gene therapies approved annually by 2026, accelerating commercialization. Major end-use sectors include hospitals, specialty clinics, and academic research centers, where advanced biologics are used for oncology, rare genetic disorders, and neurological diseases. Increasing investments in biotechnology innovation and regulatory support from agencies such as the European Medicines Agency (EMA) are further strengthening market growth.

Market Dynamics

Rising Prevalence of Rare Diseases and Oncology Applications Driving Market Growth

The increasing incidence of rare genetic disorders and cancer is a major driver of the ATMP market. According to the European Commission, rare diseases affect approximately 30 million people in Europe, while globally, over 300 million individuals suffer from rare conditions. ATMPs, particularly gene therapies, provide targeted and potentially curative solutions for such diseases. Additionally, oncology remains a dominant application area, with cell therapies such as CAR-T revolutionizing cancer treatment. The International Agency for Research on Cancer (IARC) reports that global cancer cases are expected to reach 30 million by 2040, driving demand for innovative therapies. Between 2025 and 2026, companies are focusing on expanding their ATMP portfolios. Strategic initiatives such as partnerships, acquisitions, and regulatory approvals are enhancing market penetration. Increased R&D spending by pharmaceutical companies and support from organizations like PhRMA are accelerating innovation and commercialization.

High Treatment Costs and Manufacturing Complexities Restraining Market Growth

Despite strong growth, the ATMP market faces significant challenges related to high treatment costs and complex manufacturing processes. Many gene therapies are priced above $1 million per treatment, creating affordability concerns and limiting widespread adoption. Manufacturing ATMPs involves sophisticated processes such as viral vector production and cell engineering, which require specialized infrastructure and strict regulatory compliance. According to the OECD, healthcare expenditure continues to rise globally, putting pressure on reimbursement systems and limiting accessibility to high-cost therapies. Supply chain constraints, including cold chain logistics and limited production scalability, further hinder market expansion. However, companies are investing in automation and scalable manufacturing technologies to address these issues. Innovations in gene editing and non-viral delivery systems are expected to reduce costs and improve accessibility in the long term.

Market Segmentation

Based on the product type, the market is segmented into gene therapy, cell therapy, tissue-engineered products, and combined ATMPs.
Based on the therapy type, the market is segmented into autologous therapies and allogeneic therapies.
Based on the technology platform, the market is segmented into viral vector-based technologies, non-viral delivery systems, and gene editing technologies.
Based on the application, the market is segmented into oncology, rare genetic disorders, cardiovascular diseases, neurological disorders, musculoskeletal disorders, ophthalmology, and immunological disorders.
Based on the end user, the market is segmented into hospitals, specialty clinics, research institutes, and academic medical centers.

Segment Analysis: Cell Therapy Segment Leads the Market

The cell therapy segment dominates the ATMP market due to its extensive application in oncology and hematological disorders. CAR-T therapies have demonstrated high efficacy in treating cancers such as leukemia and lymphoma, driving widespread adoption. Between 2022 and 2026, leading pharmaceutical companies have significantly expanded their cell therapy portfolios through acquisitions and partnerships. Increased regulatory approvals and growing clinical success rates are further boosting demand. Hospitals and specialty clinics are increasingly integrating cell therapies into treatment protocols, supporting segment growth.

Gene Editing Technologies Segment to Record Strong Growth

The gene editing technologies segment, particularly CRISPR-based therapies, is expected to witness the fastest growth during the forecast period. Advances in precision medicine and genome engineering are enabling targeted treatments for genetic disorders. Rising investments in biotechnology R&D and increasing clinical trials are accelerating the adoption of gene editing technologies. According to the World Intellectual Property Organization (WIPO), gene editing-related patent filings have grown significantly in recent years, reflecting strong innovation trends.

Regional Outlook

The global advanced therapy medicinal Products market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).

United States Leads the Market

The United States dominates the ATMP market due to strong regulatory support and advanced healthcare infrastructure. The FDA has been at the forefront of approving gene and cell therapies, enabling rapid commercialization. According to PhRMA, the U.S. biopharmaceutical industry invests over $100 billion annually in R&D, supporting innovation in advanced therapies. The presence of leading biotech companies and increasing clinical trials further strengthens market growth. Additionally, favorable reimbursement policies and high healthcare spending contribute to the widespread adoption of ATMPs in the country.

China to Record Strong Growth

China is expected to witness the fastest growth in the ATMP market, driven by expanding biotechnology capabilities and increasing government support. According to the OECD, China’s healthcare expenditure has been growing steadily, supporting infrastructure development and research activities. The country is investing heavily in gene therapy research and manufacturing capabilities. Increasing clinical trials and collaborations with global pharmaceutical companies are enhancing market penetration. Additionally, rising demand for advanced treatments and improving regulatory frameworks are accelerating market growth in China.

Competitive Landscape

The ATMP market is highly competitive and innovation-driven, characterized by strong R&D investments and strategic collaborations. Companies are focusing on expanding their product pipelines and enhancing manufacturing capabilities to gain a competitive edge. Key players such as Novartis AG, Gilead Sciences Inc. (Kite Pharma), Bristol-Myers Squibb Company, Johnson & Johnson, and Roche Holding AG (Spark Therapeutics) are leading the market. These companies are actively investing in gene therapy and cell therapy technologies, strengthening their global presence through partnerships and acquisitions.

Recent Developments

In March 2026, Rocket Pharmaceuticals received FDA approval for a gene therapy for Leukocyte Adhesion Deficiency-I (LAD-I).

In January 2026, Novartis announced the strategic prioritization of three emerging technology platforms, including gene & cell therapy, radioligand therapy, and RNA, as part of its pure-play innovative medicine strategy.

The Report Covers

Market value data analysis of 2025 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global advanced therapy medicinal products market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying ‘who-stands-where’ in the market.

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Advanced Therapy Medicinal Products Market Sales Analysis – Product Type | Therapy Type | Technology Platform | Application | End User ($ Million)
Advanced Therapy Medicinal Products Market Sales Performance of Top Countries

1.1 Research Methodology

Primary Research Approach
Secondary Research Approach

1.2 Market Snapshot

Market Overview and Insights

2.1 Scope of the Study

2.2 Analyst Insight & Current Market Trends

2.2.1 Key Advanced Therapy Medicinal Products Market Trends

2.2.2 Market Recommendations

2.3 Porter's Five Forces Analysis for the Advanced Therapy Medicinal Products Market

2.3.1 Competitive Rivalry

2.3.2 Threat of New Entrants

2.3.3 Bargaining Power of Suppliers

2.3.4 Bargaining Power of Buyers

2.3.5 Threat of Substitutes

Market Determinants

3.1 Market Drivers

3.1.1 Drivers For Global Advanced Therapy Medicinal Products Market : Impact Analysis

3.2 Market Pain Points and Challenges

3.2.1 Restraints For Global Advanced Therapy Medicinal Products Market : Impact Analysis

3.3 Market Opportunities

3.3.1 Opportunities For Global Advanced Therapy Medicinal Products Market : Impact Analysis

Competitive Landscape

4.1 Competitive Dashboard – Advanced Therapy Medicinal Products Market Revenue and Share by Manufacturers

Advanced Therapy Medicinal Products Market Size Product Comparison Analysis
Top Market Player Ranking Matrix

4.2 Key Company Analysis

4.2.1 Novartis AG

4.2.1.1 Overview

4.2.1.2 Product Portfolio

4.2.1.3 Financial Analysis

4.2.1.4 SWOT Analysis

4.2.1.5 Business Strategy

4.2.2 Gilead Sciences Inc. (Kite Pharma)

4.2.2.1 Overview

4.2.2.2 Product Portfolio

4.2.2.3 Financial Analysis

4.2.2.4 SWOT Analysis

4.2.2.5 Business Strategy

4.2.3 Bristol-Myers Squibb Company

4.2.3.1 Overview

4.2.3.2 Product Portfolio

4.2.3.3 Financial Analysis

4.2.3.4 SWOT Analysis

4.2.3.5 Business Strategy

4.2.4 Johnson & Johnson (Legend Biotech)

4.2.4.1 Overview

4.2.4.2 Product Portfolio

4.2.4.3 Financial Analysis

4.2.4.4 SWOT Analysis

4.2.4.5 Business Strategy

4.2.5 Roche Holding AG (Spark Therapeutics)

4.2.5.1 Overview

4.2.5.2 Product Portfolio

4.2.5.3 Financial Analysis

4.2.5.4 SWOT Analysis

4.2.5.5 Business Strategy

4.3 Top Winning Strategies by Market Players

4.3.1 Merger and Acquisition

4.3.2 Product Launch

4.3.3 Partnership And Collaboration

Global Advanced Therapy Medicinal Products Market Sales Analysis by Product Type ($ Million)

5.1 Gene Therapy
5.2 Cell Therapy
5.3 Tissue Engineered Products
5.4 Combined ATMPs

Global Advanced Therapy Medicinal Products Market Sales Analysis by Therapy Type ($ Million)

6.1 Autologous Therapies
6.2 Allogeneic Therapies

Global Advanced Therapy Medicinal Products Market Sales Analysis by Technology Platform ($ Million)

7.1 Viral Vector-Based Technologies
7.2 Non-Viral Delivery Systems
7.3 Gene Editing Technologies

Global Advanced Therapy Medicinal Products Market Sales Analysis by Application ($ Million)

8.1 Oncology
8.2 Rare Genetic Disorders
8.3 Cardiovascular Diseases
8.4 Neurological Disorders
8.5 Musculoskeletal Disorders
8.6 Ophthalmology
8.7 Immunological Disorders

Global Advanced Therapy Medicinal Products Market Sales Analysis by End User ($ Million)

9.1 Hospitals
9.2 Specialty Clinics
9.3 Research Institutes
9.4 Academic Medical Centers

Regional Analysis

10.1 North American Advanced Therapy Medicinal Products Market Sales Analysis – Product Type | Therapy Type | Technology Platform | Application | End User ($ Million)

10.1.1 United States

10.1.2 Canada

10.2 European Advanced Therapy Medicinal Products Market Sales Analysis – Product Type | Therapy Type | Technology Platform | Application | End User ($ Million)

10.2.1 UK

10.2.2 Germany

10.2.3 Italy

10.2.4 Spain

10.2.5 France

10.2.6 Russia

10.2.7 Rest of Europe

10.3 Asia-Pacific Advanced Therapy Medicinal Products Market Sales Analysis – Product Type | Therapy Type | Technology Platform | Application | End User ($ Million)

10.3.1 China

10.3.2 Japan

10.3.3 South Korea

10.3.4 India

10.3.5 Australia & New Zealand

10.3.6 ASEAN Countries

10.3.7 Rest of Asia-Pacific

10.4 Rest of the World Advanced Therapy Medicinal Products Market Sales Analysis – Product Type | Therapy Type | Technology Platform | Application | End User ($ Million)

10.4.1 Latin America

10.4.2 Middle East and Africa

Company Profiles

11.1 Allogene Therapeutics Inc.

11.1.1 Quick Facts

11.1.2 Company Overview

11.1.3 Product Portfolio

11.1.4 Business Strategies

11.2 Amgen Inc.

11.2.1 Quick Facts

11.2.2 Company Overview

11.2.3 Product Portfolio

11.2.4 Business Strategies

11.3 Autolus Therapeutics plc

11.3.1 Quick Facts

11.3.2 Company Overview

11.3.3 Product Portfolio

11.3.4 Business Strategies

11.4 BioMarin Pharmaceutical Inc.

11.4.1 Quick Facts

11.4.2 Company Overview

11.4.3 Product Portfolio

11.4.4 Business Strategies

11.5 bluebird bio Inc.

11.5.1 Quick Facts

11.5.2 Company Overview

11.5.3 Product Portfolio

11.5.4 Business Strategies

11.6 CRISPR Therapeutics AG

11.6.1 Quick Facts

11.6.2 Company Overview

11.6.3 Product Portfolio

11.6.4 Business Strategies

11.7 CSL Limited

11.7.1 Quick Facts

11.7.2 Company Overview

11.7.3 Product Portfolio

11.7.4 Business Strategies

11.8 Editas Medicine Inc.

11.8.1 Quick Facts

11.8.2 Company Overview

11.8.3 Product Portfolio

11.8.4 Business Strategies

11.9 Fate Therapeutics Inc.

11.9.1 Quick Facts

11.9.2 Company Overview

11.9.3 Product Portfolio

11.9.4 Business Strategies

11.10 Intellia Therapeutics Inc.

11.10.1 Quick Facts

11.10.2 Company Overview

11.10.3 Product Portfolio

11.10.4 Business Strategies

11.11 Krystal Biotech Inc.

11.11.1 Quick Facts

11.11.2 Company Overview

11.11.3 Product Portfolio

11.11.4 Business Strategies

11.12 Mesoblast Limited

11.12.1 Quick Facts

11.12.2 Company Overview

11.12.3 Product Portfolio

11.12.4 Business Strategies

11.13 Orchard Therapeutics plc

11.13.1 Quick Facts

11.13.2 Company Overview

11.13.3 Product Portfolio

11.13.4 Business Strategies

11.14 Pfizer Inc.

11.14.1 Quick Facts

11.14.2 Company Overview

11.14.3 Product Portfolio

11.14.4 Business Strategies

11.15 Sanofi S.A.

11.15.1 Quick Facts

11.15.2 Company Overview

11.15.3 Product Portfolio

11.15.4 Business Strategies

11.16 Sarepta Therapeutics Inc.

11.16.1 Quick Facts

11.16.2 Company Overview

11.16.3 Product Portfolio

11.16.4 Business Strategies

11.17 Smith & Nephew plc

11.17.1 Quick Facts

11.17.2 Company Overview

11.17.3 Product Portfolio

11.17.4 Business Strategies

11.18 Takeda Pharmaceutical Company

11.18.1 Quick Facts

11.18.2 Company Overview

11.18.3 Product Portfolio

11.18.4 Business Strategies

11.19 uniQure N.V.

11.19.1 Quick Facts

11.19.2 Company Overview

11.19.3 Product Portfolio

11.19.4 Business Strategies

11.20 Vericel Corporation

11.20.1 Quick Facts

11.20.2 Company Overview

11.20.3 Product Portfolio

11.20.4 Business Strategies

1 Global Advanced Therapy Medicinal Products Market Research and Analysis by Product Type, 2025–2035 ($ Million)

2 Global Gene Therapy Advanced Therapy Medicinal Products Market Research and Analysis by Region, 2025–2035 ($ Million)

3 Global Cell Therapy Advanced Therapy Medicinal Products Market Research and Analysis by Region, 2025–2035 ($ Million)

4 Global Tissue Engineered Products Advanced Therapy Medicinal Products Market Research and Analysis by Region, 2025–2035 ($ Million)

5 Global Combined ATMPs Advanced Therapy Medicinal Products Market Research and Analysis by Region, 2025–2035 ($ Million)

6 Global Advanced Therapy Medicinal Products Market Research and Analysis by Therapy Type, 2025–2035 ($ Million)

7 Global Autologous Therapies Advanced Therapy Medicinal Products Market Research and Analysis by Region, 2025–2035 ($ Million)

8 Global Allogeneic Therapies Advanced Therapy Medicinal Products Market Research and Analysis by Region, 2025–2035 ($ Million)

9 Global Advanced Therapy Medicinal Products Market Research and Analysis by Technology Platform, 2025–2035 ($ Million)

10 Global Viral Vector-Based Technologies Advanced Therapy Medicinal Products Market Research and Analysis by Region, 2025–2035 ($ Million)

11 Global Non-Viral Delivery Systems Advanced Therapy Medicinal Products Market Research and Analysis by Region, 2025–2035 ($ Million)

12 Global Gene Editing Technologies Advanced Therapy Medicinal Products Market Research and Analysis by Region, 2025–2035 ($ Million)

13 Global Advanced Therapy Medicinal Products Market Size for Oncology Research and Analysis by Region, 2025–2035 ($ Million)

14 Global Advanced Therapy Medicinal Products Market Size for Rare Genetic Disorders Research and Analysis by Region, 2025–2035 ($ Million)

15 Global Market by Region

16 North America Advanced Therapy Medicinal Products Market Research and Analysis by Country, 2025–2035 ($ Million)

17 Europe Advanced Therapy Medicinal Products Market Research and Analysis by Country, 2025–2035 ($ Million)

18 Asia-Pacific Advanced Therapy Medicinal Products Market Research and Analysis by Country, 2025–2035 ($ Million)

19 Rest of the World Advanced Therapy Medicinal Products Market Research and Analysis by Region, 2025–2035 ($ Million)

LIST OF FIGURES

1 Global Advanced Therapy Medicinal Products Market Share by Segment, 2025 Vs 2035 (%)

2 Global Gene Therapy Advanced Therapy Medicinal Products Market Share by Region, 2025 Vs 2035 (%)

3 Global Cell Therapy Advanced Therapy Medicinal Products Market Share by Region, 2025 Vs 2035 (%)

4 Global Tissue Engineered Products Advanced Therapy Medicinal Products Market Share by Region, 2025 Vs 2035 (%)

5 Global Combined ATMPs Advanced Therapy Medicinal Products Market Share by Region, 2025 Vs 2035 (%)

6 Global Advanced Therapy Medicinal Products Market Size for Oncology Market Share by Region, 2025 Vs 2035 (%)

8 United States Advanced Therapy Medicinal Products Market Size, 2025-2035 ($ Million)

9 Canada Advanced Therapy Medicinal Products Market Size, 2025-2035 ($ Million)

10 UK Advanced Therapy Medicinal Products Market Size, 2025-2035 ($ Million)

11 France Advanced Therapy Medicinal Products Market Size, 2025-2035 ($ Million)

12 Germany Advanced Therapy Medicinal Products Market Size, 2025-2035 ($ Million)

13 Italy Advanced Therapy Medicinal Products Market Size, 2025-2035 ($ Million)

14 Spain Advanced Therapy Medicinal Products Market Size, 2025-2035 ($ Million)

15 Russia Advanced Therapy Medicinal Products Market Size, 2025-2035 ($ Million)

16 India Advanced Therapy Medicinal Products Market Size, 2025-2035 ($ Million)

17 China Advanced Therapy Medicinal Products Market Size, 2025-2035 ($ Million)

18 Japan Advanced Therapy Medicinal Products Market Size, 2025-2035 ($ Million)

19 South Korea Advanced Therapy Medicinal Products Market Size, 2025-2035 ($ Million)

20 Australia & New Zealand Advanced Therapy Medicinal Products Market Size, 2025-2035 ($ Million)

21 ASEAN Advanced Therapy Medicinal Products Market Size, 2025-2035 ($ Million)

22 Rest of Asia-Pacific Advanced Therapy Medicinal Products Market Size, 2025-2035 ($ Million)

23 Latin America Advanced Therapy Medicinal Products Market Size, 2025-2035 ($ Million)

24 Middle East & Africa Advanced Therapy Medicinal Products Market Size, 2025-2035 ($ Million)